“…Conversely, many clinical studies have showed that the most frequent primary non-thyroidal malignancy resulting in symptomatic or clinically evident thyroid metastases was RCC. 3,13,14) In the present study, the lung was the most frequent origin of thyroid metastases, corresponded with autopsy studies. We supposed that the subclinical manifestation of thyroid metastases was detected more frequently than the past, because the clinical application of CT and 18 FDG PET-CT has gradually been increasing in the patients with malignancies.…”
“…Conversely, many clinical studies have showed that the most frequent primary non-thyroidal malignancy resulting in symptomatic or clinically evident thyroid metastases was RCC. 3,13,14) In the present study, the lung was the most frequent origin of thyroid metastases, corresponded with autopsy studies. We supposed that the subclinical manifestation of thyroid metastases was detected more frequently than the past, because the clinical application of CT and 18 FDG PET-CT has gradually been increasing in the patients with malignancies.…”
“…Thyrotoxicosis, as observed in our patient, may be caused by invasion and damage to thyroid follicles by rapid growing metastases, with release of hormone into the bloodstream, or by the production of thyroid hormones by the tumor cells (13,22). Unfortunately, the study of the etiology of the thyrotoxicosis in our patient's case was incomplete.…”
SUMMARYThyroid metastases are rare in clinical practice. We describe the case of an 85-year-old woman who was referred to our department due to a multinodular goiter with compressive symptoms and subclinical hyperthyroidism. The patient was also undergoing evaluation for a polyp in her left nasal cavity, which was then diagnosed as a malignant melanoma of the nasal mucosa. A thoracoabdominal magnetic resonance imaging obtained for cancer staging revealed a > 50% tracheal obstruction caused by the goiter. The patient underwent simultaneous total thyroidectomy and melanoma excision. Histological analysis of the thyroid showed the presence of multiple metastatic foci from the melanoma. Due to the patient's age, a decision was made to maintain her under surveillance and administer palliative treatment if necessary. Although metastases to the thyroid are rare, they should be considered in the differential diagnosis of thyroid lesions in patients with a known primary tumor. The thyroidectomy, performed in this patient's case, allowed the diagnosis of the metastases and relief of compressive symptoms caused by the goiter. Arch Endocrinol Metab. 2017;61(2):193-7.
“…Although most patients reported to have thyroid metastases had advanced primary carcinomas, in some patients [27], including ours, the thyroid gland was the only site of metastasis. US guided FNAB is optimal in the diagnosis of thyroid tumors [28], with many reports of thyroid metastases also based on FNAB results [13,14,[17][18][19][20][21][22]. FNAB of the thyroid in our patient suggested a poorly differentiated carcinoma favoring metastasis but not expressing thyroglobulin, leading us to perform thyroid surgery.…”
Section: Discussionmentioning
confidence: 57%
“…The incidence of thyroid metastases in clinical reports seems to have increased recently [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22], with the most common primary carcinoma site being the kidney, followed by breast and lung [8][9][10][11][12][13][14].…”
Section: Discussionmentioning
confidence: 99%
“…Clinical reports have suggested, however, that the incidence of these metastases is increasing. The most common primary carcinoma sites in clinical reports are the kidneys, breasts, and lungs [8][9][10][11][12][13][14], although other primary carcinomas can also metastasize to the thyroid gland [15][16][17][18][19][20][21][22][23][24][25][26][27].Hepatocellular carcinoma (HCC) rarely metastasizes to the thyroid [6,23,[25][26][27]. Here, we describe a patient with an HCC metastasis to within a medullary thyroid carcinoma (MTC), that is, a tumor-in-tumor metastasis.…”
Metastasis to the thyroid gland is uncommon, with previous autopsy series showing incidence rates ranging from 0.5% to 10.1% [1][2][3][4][5][6][7]. Clinical reports have suggested, however, that the incidence of these metastases is increasing. The most common primary carcinoma sites in clinical reports are the kidneys, breasts, and lungs [8][9][10][11][12][13][14], although other primary carcinomas can also metastasize to the thyroid gland [15][16][17][18][19][20][21][22][23][24][25][26][27].Hepatocellular carcinoma (HCC) rarely metastasizes to the thyroid [6,23,[25][26][27]. Here, we describe a patient with an HCC metastasis to within a medullary thyroid carcinoma (MTC), that is, a tumor-in-tumor metastasis. To our knowledge, this is the first such clinically diagnosed case.Due to the relatively short survival times of patients with distant metastases, solitary thyroid tumors in patients with advanced carcinoma are not routinely evaluated. However, imaging modalities, including fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and ultrasonography (US) guided fine-needle aspiration biopsy (FNAB) of newly detected Hepatocellular carcinoma eats medullary thyroid carcinoma, a case of tumor-in-tumor metastasis abstract. Carcinoma metastasis to the thyroid is uncommon, but may be increasing. We describe here a patient with a metastasis of hepatocellular carcinoma (HCC) presenting within a medullary thyroid carcinoma (MTC). The thyroid tumor was detected synchronously with the hepatic lesion by FDG-PET imaging, and HCC metastasis within MTC was confirmed by histological analysis of the thyroid gland.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.